Unpublished conference/Abstract (Scientific congresses and symposiums)
Administration of Third-Party Mesenchymal Stromal Cells at the Time of Kidney Transplantation: Interim Safety Analysis at One-Year Follow-Up
WEEKERS, Laurent; ERPICUM, Pauline; DETRY, Olivier et al.
201724th Annual Meeting
 

Files


Full Text
Weekers.MSC.KTx.BT2017.pdf
Publisher postprint (224.88 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Mesenchymal stromal cells (MSC)-based therapy has been proposed in kidney transplantation (KTx). We report on the 1-year follow-up of an open-label phase I trial using MSC in KTx. On postoperative day 3, third-party MSC (~2.0x106/kg) were administered to 7 non-immunized first-transplant recip- ients from deceased donors, under standard immunosuppression (Basiliximab, Tacrolimus, MMF and steroids). No HLA matching was required for MSC donors. Seven comparable KTx recipients were included as controls. Informed consent was obtained. No side-effect was noted at the time of MSC injection. Still, 1 patient with a history of ischemic heart disease had a NSTEMI ~3h after MSC infusion. Ten months after KTx, 1 MSC patient had type B aortic dissection and STEMI. Four MSC patients had at least 1 opportunistic infection, whereas 3 controls had polyoma-BK viremia. At day 14, eGFR in MSC and control groups was 47.1 ± 6.8 and 39.7 ± 5.9 ml/min, respectively (p, 0.05). At 1 year, eGFR in MSC and control groups was 46.5 ± 18.6 and 54.2 ± 16.3 ml/min, respectively (p, 0.42). Per-cause biopsies evidenced 1 bor- derline and 1 acute rejections in MSC group, whereas no AR was biopsy-proven in controls. Three patients developed anti-HLA antibodies against MSC (n=1) or shared kidney/MSC (n=2) mismatches.MSC infusion was safe in all patients except one. Incidence of opportunist infections was similar in both groups. No difference in eGFR was found at 1-year post KTx. Putative immunization against MSC was observed in 3 patients.
Disciplines :
Urology & nephrology
Surgery
Author, co-author :
WEEKERS, Laurent  ;  Centre Hospitalier Universitaire de Liège - CHU > Service de néphrologie
ERPICUM, Pauline ;  Centre Hospitalier Universitaire de Liège - CHU > Service de néphrologie
DETRY, Olivier  ;  Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdo, sénologique, endocrine et de transplantation
BONVOISIN, Catherine ;  Centre Hospitalier Universitaire de Liège - CHU > Service de néphrologie
DELBOUILLE, Marie-Hélène ;  Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdo, sénologique, endocrine et de transplantation
LECHANTEUR, Chantal ;  Centre Hospitalier Universitaire de Liège - CHU > Thérapie cellulaire
BRIQUET, Alexandra ;  Centre Hospitalier Universitaire de Liège - CHU > Service d'hématologie clinique
BAUDOUX, Etienne  ;  Centre Hospitalier Universitaire de Liège - CHU > Thérapie cellulaire
JOURET, François  ;  Centre Hospitalier Universitaire de Liège - CHU > Service de néphrologie
BEGUIN, Yves  ;  Centre Hospitalier Universitaire de Liège - CHU > Service d'hématologie clinique
Language :
English
Title :
Administration of Third-Party Mesenchymal Stromal Cells at the Time of Kidney Transplantation: Interim Safety Analysis at One-Year Follow-Up
Publication date :
16 March 2017
Event name :
24th Annual Meeting
Event organizer :
Belgian Transplantation Society
Event place :
Bruxelles, Belgium
Event date :
du 16 au 17 Mars 2017
Available on ORBi :
since 26 April 2017

Statistics


Number of views
46 (7 by ULiège)
Number of downloads
17 (3 by ULiège)

Bibliography


Similar publications



Contact ORBi